

## Datasheet: PIP012

**BATCH NUMBER 164669**

<b>Description:</b>	NATIVE INFLUENZA B ANTIGEN
<b>Name:</b>	INFLUENZA B ANTIGEN
<b>Format:</b>	Inactivated Pathogen
<b>Product Type:</b>	Antigen
<b>Quantity:</b>	1 ml

## Product Details

**Applications**

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	<b>Yes</b>	<b>No</b>	<b>Not Determined</b>	<b>Suggested Dilution</b>
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Viral
<b>Product Form</b>	Inactivated Influenza B antigen - liquid
<b>Preparation</b>	Influenza B, strain Hong Kong 5/72, cultured in MDCK cells. Clarified and concentrated cell culture supernatant. The antigen preparation is inactivated by gamma radiation.
<b>Buffer Solution</b>	Eagle's Minimum Essential Medium
<b>Preservative Stabilisers</b>	None present
<b>Approx. Protein Concentrations</b>	Current, batch-specific concentration 1.15 mg/ml

**Product Information** This product is a native influenza B antigen. Influenza is an acute infection of the respiratory tract caused by the Influenza virus, of which there are several different types.

Influenza B is only known to infect humans and seals. Influenza infection in humans causes chills, fever, pharyngitis, muscle pain, headaches, coughing and weakness. The

virus is transmitted through the air by coughs or sneezes or through saliva, nasal secretions, faeces and blood. Infection may occur through direct contact with infected bodily fluid or contaminated surfaces. Influenza B viruses mutate slower than Influenza A, but fast enough that lasting immunity is not possible. The slower mutation rate and limited host range makes Influenza B less like to cause pandemics than Influenza A.

---

**Activity** 20480 HA units/ml as determined by hemagglutination endpoint assay.

---

**Instructions For Use** The preparation might be slightly cloudy or contain minor precipitate upon thawing. Do not sonicate and do not clarify prior to dilution at least 10-fold with working buffer.

---

**Storage** Store at -70°C.  
Storage in frost-free freezers is not recommended.  
This product should be stored undiluted.  
Avoid repeated freezing and thawing as this may denature the protein.

---

**Guarantee** Guaranteed until date of expiry. Please see product label.

---

**Health And Safety Information** Material Safety Datasheet documentation #10286 available at:  
<https://www.bio-rad-antibodies.com/SDS/PIP012>  
10286

This product has been rendered inactive by gamma radiation. However this material should still be handled as infectious and should be disposed of appropriately.

---

**Regulatory** For research purposes only

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M419059:230516'

**Printed on 16 May 2023**

---

© 2023 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)